electroCore, Inc. reports developments in bioelectronic medicine and wellness products built around non-invasive vagus nerve stimulation, or nVNS. Company news commonly covers prescription gammaCore for migraine, Quell Fibromyalgia, Truvaga and Truvaga Plus consumer wellness products, and TAC-STIM for human performance.
Recurring updates include financial results, U.S. prescription sales activity, direct-to-consumer wellness sales, product-line commercialization, clinical research involving gammaCore nVNS, and participation in healthcare and investor conferences. News also highlights applications of vagus nerve stimulation across prescription medical uses and consumer wellness settings.
electroCore (Nasdaq: ECOR) reported preliminary unaudited full-year 2025 results and guidance: record revenue expected at $31.8–$32.0 million, representing ~26% growth versus 2024 ($25.2M). Fourth-quarter 2025 revenue is anticipated at $9.0–$9.2 million, about 30% growth versus Q4 2024. The company ended 2025 with approximately $11.6 million in cash, cash equivalents, and marketable securities, down from ~$13.2 million at September 30, 2025. electroCore described these figures as preliminary unaudited guidance and plans a full operational and financial update on its Q4 and FY2025 earnings call in March 2026.
electroCore (Nasdaq: ECOR) announced a peer‑reviewed study showing its TAC‑STIM™ transcutaneous vagal nerve stimulation (tVNS) device improved mood, task performance, and learning in 70 active‑duty U.S. Air Force trainees.
Key results include statistically significant reductions in distress (p<0.001), higher perceived ability (p=0.020), increased energy (p=0.002), and objective performance gains in intelligence tasks and instructor assessments (group main effect p=0.020). Findings were sustained across four days and will be presented at AHFE2025 on December 8, 2025.
electroCore (Nasdaq: ECOR) announced that company management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 20, 2025 at The Westin NY Grand Central Hotel.
Management will host one-on-one meetings throughout the day. Investors seeking a meeting should contact their Canaccord Genuity sales representative or email electroCore Investor Relations at ecor@fnkir.com.
electroCore (Nasdaq: ECOR) reported record Q3 2025 net sales of $8.7 million, up 33% year-over-year, and year-to-date net sales of $22.8 million, up 26% versus the first nine months of 2024. Total cash was $13.2 million at September 30, 2025. Management cited strong prescription growth in the VA (gammaCore +16% in VA) and Truvaga record quarterly sales of $1.7 million; Quell Fibromyalgia contributed $530,000 in VA revenues and $595,000 of product sales in Q3. GAAP net loss was $3.4 million (loss per share $0.40); adjusted EBITDA net loss was $2.0 million. The company raised full-year 2025 revenue guidance to $31.5–$32.5 million and expects to reach $12.0 million quarterly revenue and first positive adjusted EBITDA in H2 2026.
electroCore (Nasdaq: ECOR) will report third quarter results for the period ended September 30, 2025 after market close on Wednesday, November 5, 2025. Management will host a results webinar on November 5, 2025 at 4:30 PM EST to review the financial results and answer questions.
Investors can join via dial-in (646) 931-3860, Webinar ID 822 9598 1338, passcode 454695, or register using the provided registration link to participate and ask questions.
electroCore (NASDAQ: ECOR) announced on October 3, 2025 that Jennifer Hayes will join the company as Vice President, Human Resources and Employee Success, effective October 6, 2025.
The Compensation Committee granted 10,000 restricted stock units (RSUs) as an inducement under NASDAQ Listing Rule 5635(c)(4). The RSUs vest one-third on each of the first, second and third anniversaries of the grant, subject to continued employment, and will be settled in shares of common stock upon vesting.
electroCore (Nasdaq: ECOR) announced promising results from a peer-reviewed study published in Frontiers in Neurology demonstrating the effectiveness of their gammaCore® non-invasive vagus nerve stimulation (nVNS) device in treating mild traumatic brain injury (mTBI) symptoms.
The study, involving 102 patients, showed significant improvements across multiple symptom categories when gammaCore was used as an adjunctive treatment. 34% of patients reported meaningful improvement in at least half of their persistent symptoms, with benefits observed regardless of time since injury. The treatment showed effectiveness in 16 out of 22 symptom categories, including post-traumatic headache, dizziness, and depression, with no device-related adverse events reported.
electroCore (NASDAQ:ECOR) has secured a significant regulatory milestone as its gammaCore™ Sapphire (nVNS) device received reimbursement approval from Belgium's National Institute for Health and Disability Insurance (RIZIV/INAMI). The coverage, effective October 1, 2025, will provide Belgian patients suffering from cluster headaches access to this bioelectronic treatment.
The approval was achieved through collaboration with Silvert Medical, electroCore's distribution partner in Belgium, and is supported by strong clinical evidence demonstrating the therapy's efficacy and cost-effectiveness. Prof. Paemeleire from Ghent University Hospital's Headache Clinic endorsed the decision, highlighting the benefits of non-invasive vagus nerve stimulation for patients.
[ "Secured reimbursement approval in Belgium, expanding market access", "Partnership with established distributor Silvert Medical for market penetration", "Strong clinical evidence supporting therapy efficacy and cost-effectiveness", "Strategic position in central Europe for potential expansion to neighboring countries" ]electroCore (Nasdaq: ECOR) announced that its Truvaga™ Plus device has been awarded "Best Relaxation Gadget" in Esquire's 2025 Sleep Awards. The handheld vagus nerve stimulation (nVNS) device was selected by Esquire's editors after extensive testing, recognized for its ability to promote relaxation and better sleep through two-minute sessions.
The device stands out for its drug-free approach to calming the nervous system, reducing stress, and enhancing sleep quality. This recognition in Esquire's annual Sleep Awards, which highlights the most effective sleep and recovery solutions, serves as third-party validation for consumers seeking alternative sleep improvement methods.
electroCore (NASDAQ: ECOR), a bioelectronic medicine and wellness company, has appointed Andy Brown as VP, Corporate Controller effective September 9, 2025. As part of his employment package, Brown was granted 10,000 restricted stock units (RSUs) as an inducement award under NASDAQ Listing Rule 5635(c)(4).
The RSUs will vest in three equal installments of 33% each on the first, second, and third anniversaries of the grant date, contingent upon Brown's continued employment. Upon vesting, the RSUs will be converted into shares of electroCore's common stock.
[]